TScan Therapeutics, Inc. (NASDAQ:TCRX) · earnings preview
Quarter
Q2
EPS estimate to actual
-$0.22
Revenue estimate to actual
$2.6M
At a glance
Key takeaways
01TScan Therapeutics (TCRX) will report Q2 2026 earnings on August 11, 2026 after market close, with analysts expecting a loss of $0.22 per share compared to breakeven in the prior year quarter.
02The company's stock trades at $0.77 with a market capitalization of $61.0 million, and revenue is expected to reach $2.5 million, representing year-over-year growth.
03Recent earnings history shows the company missed Q1 2026 estimates by 22.2% (reporting $-0.22 EPS versus $-0.18 expected) but beat Q4 2025 estimates by 33.3%.
Earnings Results
TScan Therapeutics, Inc. (NASDAQ:TCRX) is scheduled to report its Q2 earnings results on August 11, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.22, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at $2.5M, up from a year ago.
Company Overview
The stock currently trades at $0.77 with a market capitalization of $61.0M.
Ahead of TScan Therapeutics, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking TScan Therapeutics, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.